Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
BMJ ; 363: k5130, 2018 Dec 18.
Article in English | MEDLINE | ID: mdl-30563885

ABSTRACT

WHAT IS THE ROLE OF DUAL ANTIPLATELET THERAPY AFTER HIGH RISK TRANSIENT ISCHAEMIC ATTACK OR MINOR STROKE? SPECIFICALLY, DOES DUAL ANTIPLATELET THERAPY WITH A COMBINATION OF ASPIRIN AND CLOPIDOGREL LEAD TO A GREATER REDUCTION IN RECURRENT STROKE AND DEATH OVER THE USE OF ASPIRIN ALONE WHEN GIVEN IN THE FIRST 24 HOURS AFTER A HIGH RISK TRANSIENT ISCHAEMIC ATTACK OR MINOR ISCHAEMIC STROKE? AN EXPERT PANEL PRODUCED A STRONG RECOMMENDATION FOR INITIATING DUAL ANTIPLATELET THERAPY WITHIN 24 HOURS OF THE ONSET OF SYMPTOMS, AND FOR CONTINUING IT FOR 10-21 DAYS CURRENT PRACTICE IS TYPICALLY TO USE A SINGLE DRUG.


Subject(s)
Aspirin/administration & dosage , Brain Ischemia/drug therapy , Clopidogrel/administration & dosage , Ischemic Attack, Transient/drug therapy , Platelet Aggregation Inhibitors/administration & dosage , Stroke/drug therapy , Brain Ischemia/prevention & control , Humans , Ischemic Attack, Transient/prevention & control , Practice Guidelines as Topic , Recurrence , Secondary Prevention , Stroke/prevention & control , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...